Form 4: ORAMED COO & CBO Joshua Hexter Acquires 95,889 RSUs

ORAMED PHARMACEUTICALS INC. COO & CBO Joshua Hexter reported the acquisition of 95,889 Restricted Stock Units, vesting quarterly starting April 1, 2026.

Summary

• Joshua Hexter, COO & CBO of ORAMED PHARMACEUTICALS INC., acquired 95,889 Restricted Stock Units (RSUs).
• The RSUs represent the right to receive one share of common stock, par value $0.012 per share, of the Issuer.
• These RSUs will vest ratably in 8 quarterly installments, commencing April 1, 2026.
• Following this transaction, Hexter beneficially owns 1,160,384 shares directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices that align management's long-term interests with shareholder value through equity grants.

Positives

• The grant of 95,889 Restricted Stock Units to a key executive, Joshua Hexter, aligns his interests with long-term shareholder value.
• The vesting schedule over two years (8 quarterly installments) encourages executive retention and sustained performance.

Future Outlook

The vesting schedule for the acquired Restricted Stock Units extends into the future, with installments beginning April 1, 2026, and continuing quarterly for two years, indicating a long-term incentive structure for the COO & CBO.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units (RSUs) to key executives like a COO & CBO is a standard practice in the pharmaceutical and biotechnology industry. This compensation structure is designed to align executive incentives with long-term company performance and shareholder value, common among peers seeking to retain top talent and foster commitment to strategic goals.

Comparison to Industry Standards

• The grant of RSUs as a form of executive compensation is a common practice across the pharmaceutical industry, comparable to companies like Pfizer, Merck, and Johnson & Johnson, which frequently use equity awards to incentivize leadership.
• The vesting schedule of 8 quarterly installments over two years is typical for executive equity grants, aiming to promote long-term retention and performance, similar to programs seen at biotech firms such as Amgen or Gilead Sciences.

Stakeholder Impact

• Shareholders: The grant of RSUs to a key executive aligns management's interests with long-term shareholder value, potentially fostering sustained performance.
• Employees: May signal stability in executive leadership and a commitment to long-term incentives within the company.

Next Steps

• The Restricted Stock Units will begin vesting ratably in 8 quarterly installments starting April 1, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the grant of Restricted Stock Units. While it indicates alignment of executive interests with long-term company performance, it does not present new information that would fundamentally alter the investment thesis or warrant a change in an existing 'hold' position. It's a standard disclosure without immediate catalysts for significant price movement.

Keywords

ORAMED PHARMACEUTICALS, ORMP, Joshua Hexter, Restricted Stock Units, RSUs, Insider Trading, Executive Compensation, Stock Grant, Form 4, Beneficial Ownership